Literature DB >> 17537630

Myofiber size correlates with MTM1 mutation type and outcome in X-linked myotubular myopathy.

Christopher R Pierson1, Pankaj B Agrawal, Jessica Blasko, Alan H Beggs.   

Abstract

We aimed to correlate pathologic findings with MTM1 mutation type in a series of molecularly defined XLMTM cases. Clinical data from 15 XLMTM patients and their corresponding 16 muscle biopsies were studied. All patients were infants (range: 6-217 days old) when initially biopsied. The proportion of myofibers with central nuclei did not correlate with clinical outcome, however, morphometric studies showed that survivors had larger myofiber diameters in infancy than those who died (10.4+/-3.9microm versus 8.9+/-3microm; p<0.001). As a corollary, patients with MTM1 missense mutations had larger myofiber diameters (11.1+/-4microm), than those with truncation/deletion mutations (8.6+/-2.7microm) (controls 11.7+/-2.5microm) (p<0.0001). These data indicate that differences in myofiber size correlate with MTM1 mutation type and patient outcome. Failure to attain and/or maintain myofiber size, along with fiber type perturbations and the misplacement of myofiber nuclei and other organelles, are important components of XLMTM muscle pathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537630      PMCID: PMC2043149          DOI: 10.1016/j.nmd.2007.03.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  36 in total

Review 1.  The function of Myostatin and strategies of Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle.

Authors:  Ketan Patel; Helge Amthor
Journal:  Neuromuscul Disord       Date:  2005-01-11       Impact factor: 4.296

2.  Vimentin and desmin in maturing skeletal muscle and developmental myopathies.

Authors:  H B Sarnat
Journal:  Neurology       Date:  1992-08       Impact factor: 9.910

3.  Medical complications in long-term survivors with X-linked myotubular myopathy.

Authors:  G E Herman; M Finegold; W Zhao; B de Gouyon; A Metzenberg
Journal:  J Pediatr       Date:  1999-02       Impact factor: 4.406

Review 4.  X-linked myotubular and centronuclear myopathies.

Authors:  Christopher R Pierson; Kinga Tomczak; Pankaj Agrawal; Behzad Moghadaszadeh; Alan H Beggs
Journal:  J Neuropathol Exp Neurol       Date:  2005-07       Impact factor: 3.685

5.  Muscle biopsy without centrally located nuclei in a male child with mild X-linked myotubular myopathy.

Authors:  Christian G E L de Goede; Anna Kelsey; Helen Kingston; Pamela I Tomlin; M Imelda Hughes
Journal:  Dev Med Child Neurol       Date:  2005-12       Impact factor: 5.449

Review 6.  MTM1 mutations in X-linked myotubular myopathy.

Authors:  J Laporte; V Biancalana; S M Tanner; W Kress; V Schneider; C Wallgren-Pettersson; F Herger; A Buj-Bello; F Blondeau; S Liechti-Gallati; J L Mandel
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

7.  Characterization of mutations in the myotubularin gene in twenty six patients with X-linked myotubular myopathy.

Authors:  B M de Gouyon; W Zhao; J Laporte; J L Mandel; A Metzenberg; G E Herman
Journal:  Hum Mol Genet       Date:  1997-09       Impact factor: 6.150

8.  A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast.

Authors:  J Laporte; L J Hu; C Kretz; J L Mandel; P Kioschis; J F Coy; S M Klauck; A Poustka; N Dahl
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

Review 9.  The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies.

Authors:  C Wallgren-Pettersson; A Clarke; F Samson; M Fardeau; V Dubowitz; H Moser; T Grimm; R J Barohn; P G Barth
Journal:  J Med Genet       Date:  1995-09       Impact factor: 6.318

10.  Myotubular myopathy: morphological, immunohistochemical and clinical variation.

Authors:  T R Helliwell; I H Ellis; R E Appleton
Journal:  Neuromuscul Disord       Date:  1998-05       Impact factor: 4.296

View more
  20 in total

1.  Modeling the human MTM1 p.R69C mutation in murine Mtm1 results in exon 4 skipping and a less severe myotubular myopathy phenotype.

Authors:  Christopher R Pierson; Ashley N Dulin-Smith; Ashley N Durban; Morgan L Marshall; Jordan T Marshall; Andrew D Snyder; Nada Naiyer; Jordan T Gladman; Dawn S Chandler; Michael W Lawlor; Anna Buj-Bello; James J Dowling; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2011-11-07       Impact factor: 6.150

2.  Inhibition of activin receptor type IIB increases strength and lifespan in myotubularin-deficient mice.

Authors:  Michael W Lawlor; Benjamin P Read; Rachel Edelstein; Nicole Yang; Christopher R Pierson; Matthew J Stein; Ariana Wermer-Colan; Anna Buj-Bello; Jennifer L Lachey; Jasbir S Seehra; Alan H Beggs
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers.

Authors:  Alan H Beggs; Johann Böhm; Elizabeth Snead; Marek Kozlowski; Marie Maurer; Katie Minor; Martin K Childers; Susan M Taylor; Christophe Hitte; James R Mickelson; Ling T Guo; Andrew P Mizisin; Anna Buj-Bello; Laurent Tiret; Jocelyn Laporte; G Diane Shelton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-03       Impact factor: 11.205

Review 4.  Congenital myopathies.

Authors:  Adele D'Amico; Enrico Bertini
Journal:  Curr Neurol Neurosci Rep       Date:  2008-01       Impact factor: 5.081

5.  Differential muscle hypertrophy is associated with satellite cell numbers and Akt pathway activation following activin type IIB receptor inhibition in Mtm1 p.R69C mice.

Authors:  Michael W Lawlor; Marissa G Viola; Hui Meng; Rachel V Edelstein; Fujun Liu; Ke Yan; Elizabeth J Luna; Alexandra Lerch-Gaggl; Raymond G Hoffmann; Christopher R Pierson; Anna Buj-Bello; Jennifer L Lachey; Scott Pearsall; Lin Yang; Cecilia J Hillard; Alan H Beggs
Journal:  Am J Pathol       Date:  2014-04-13       Impact factor: 4.307

6.  Defective autophagy and mTORC1 signaling in myotubularin null mice.

Authors:  Kristina M Fetalvero; Yenyen Yu; Margaret Goetschkes; Guiqing Liang; Reginald A Valdez; Ty Gould; Ellen Triantafellow; Sebastian Bergling; Joseph Loureiro; John Eash; Victor Lin; Jeffrey A Porter; Peter M Finan; Kenneth Walsh; Yi Yang; Xiaohong Mao; Leon O Murphy
Journal:  Mol Cell Biol       Date:  2012-10-29       Impact factor: 4.272

7.  Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy.

Authors:  Michael W Lawlor; Dustin Armstrong; Marissa G Viola; Jeffrey J Widrick; Hui Meng; Robert W Grange; Martin K Childers; Cynthia P Hsu; Michael O'Callaghan; Christopher R Pierson; Anna Buj-Bello; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2013-01-09       Impact factor: 6.150

8.  Muscle length and myonuclear position are independently regulated by distinct Dynein pathways.

Authors:  Eric S Folker; Victoria K Schulman; Mary K Baylies
Journal:  Development       Date:  2012-09-05       Impact factor: 6.868

9.  The aponeurotic tension model of craniofacial growth in man.

Authors:  Richard G Standerwick; W Eugene Roberts
Journal:  Open Dent J       Date:  2009-05-22

10.  Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes.

Authors:  Roberto Silva-Rojas; Vasugi Nattarayan; Francisco Jaque-Fernandez; Raquel Gomez-Oca; Alexia Menuet; David Reiss; Marie Goret; Nadia Messaddeq; Valentina M Lionello; Christine Kretz; Belinda S Cowling; Vincent Jacquemond; Jocelyn Laporte
Journal:  Mol Ther       Date:  2021-08-08       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.